Related Experiment Video
Updated: Jul 23, 2026
09:33
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
Mechanisms of carcinogenesis: dose response
Journal of Environmental Pathology and Toxicology
|September 1, 1978
Summary
The dose-dependency of chemical carcinogenicity is debated, but evidence supports it. This study proposes a chemical process model for carcinogenesis, suggesting current risk assessments may overestimate low-level exposure hazards.
Area of Science:
- Toxicology
- Chemical Carcinogenesis
- Risk Assessment
Background:
- The dose-dependency of chemical carcinogenicity and the existence of a threshold dose remain controversial.
- Current debates often resemble religious arguments, hindering scientific consensus.
- Existing evidence supports dose-dependency, separate from the threshold concept.
Purpose of the Study:
- To review arguments surrounding chemical carcinogenicity dose-dependency and thresholds.
- To develop a chemical process model for carcinogenesis.
- To provide a scientifically sound basis for assessing low-level chemical carcinogen exposure hazards.
Main Methods:
- Review of existing literature on chemical carcinogenicity and dose-response.
- Development of a chemical process model based on DNA alkylation.
- Analysis of the fate of carcinogenic chemicals within the body.
Main Results:
- A chemical process model predicts some cancer incidence, even at low doses.
- The model suggests current stochastic statistical extrapolations may overestimate cancer risk from real-life exposures.
- Modeling reveals potential experimental approaches to understand carcinogenesis mechanisms.
Conclusions:
- Chemical carcinogenicity is dose-dependent, and the threshold concept is contentious.
- A new chemical process model offers a more scientifically sound approach to risk assessment for low-level exposures.
- Further research into chemical fate and DNA alkylation can refine hazard evaluations.
More Related Videos
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
04:12Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)
Published on: December 19, 2019
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:03Dose-Response Relationship: Overview
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:28Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly proportional to...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:21Dose Response Curve: Conventional Versus Nonmonotonic
The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...